Search / Trial NCT06235645

dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound

Launched by UNIVERSITY HOSPITAL, TOURS · Jan 23, 2024

Trial Information

Current as of October 04, 2024

Not yet recruiting

Keywords

Lung Ultrasound Rheumatoid Arthritis Interstitial Lung Disease

Description

Patients with RA and who have risk factors for RA-ILD are regularly reassessed in a rheumatology day hospital. As part of their routine follow-up, and given the absence of recommendations on screening for RA-ILD in this population, chest CT and PFT (pulmonary function tests) are regularly performed at the request of the rheumatologist. Therefore, all patients meeting the inclusion criteria and having undergone chest CT and PFT in the 6 months preceding or following their rheumatology reassessment will be offered participation in the study. Participation in the study does not alter the pa...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Adult patient (age \> 18 years) followed at CHU of Tours
  • * Diagnosis of rheumatoid arthritis validated according to ACR 2010 criteria, EULAR classification, regardless of time since diagnosis
  • * Patient who has had or will have a thoracic CT scan and PFT performed as part of routine care in the 6 months preceding or following inclusion
  • * Patient with at least two risk factors for developing RA-ILD among :
  • * Male sex or
  • * Active or former smoker assessed at 20 pack-year or
  • * Age \> 60 years or
  • * Levels of RF≥3N (rheumatoid factor) and/or anti-CCP≥3N (antibodies against cyclic citrullinated peptides) at diagnosis or at any time during the course of the disease or
  • * High RA activity score (DAS28\>3.2)
  • Exclusion Criteria:
  • * Diagnosis of congenital lung disease
  • * Diagnosis of another autoimmune pathology associated with RA (overlap syndrome) linked to the development of ILD (interstitial lung disease) (systemic sclerosis, myositis, dermatomyositis, mixed connectivitis, systemic lupus erythematosus or other ANCA vasculitis, with the exception of secondary Gougerot-Sjögren's syndromes).
  • * Current or operated lung cancer
  • * Thoracic irradiation
  • * Thoracic transplant patients
  • * Previous invasive thoracic procedures
  • * Pathologies responsible for pleural thickening (silicosis, asbestosis, known pleural plaque, pleural sequelae of tuberculosis)
  • * Pregnant or breast-feeding women
  • * Patient under legal protection (guardianship, curatorship or safeguard of justice)
  • * Patient who has objected to data processing
  • * Parenchymal infection current or less than one month old prior to LUS examination
  • * Liquid or gaseous pleural effusion

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Tours, , France

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0